About trastuzum ab + vial
HER2-targeted monoclonal antibody
Used for
- HER2-positive breast cancer
- HER2-positive metastatic stomach or gastroesophageal junction cancer
Usual adult dose
Usually 8 mg/kg IV initially, then 6 mg/kg every 3 weeks; schedules vary by cancer and treatment combination.
Common side effects
- Fever and chills during infusion
- Nausea or diarrhea
- Headache and fatigue
- Reduced heart function
Important warnings
- Can cause serious heart problems; heart function is checked before and during treatment.
- Infusion reactions can be severe, including breathing difficulties.
- May cause serious harm to an unborn baby; pregnancy testing and effective contraception are important.
- Use only for cancers confirmed to be HER2-positive.
Pregnancy
Can harm an unborn baby, including causing low amniotic fluid. Avoid during pregnancy and for 7 months after the final dose.
Breastfeeding
Breastfeeding is not recommended during treatment and for 7 months after the final dose.
Interactions
- Anthracycline chemotherapy can increase heart damage, including when given after trastuzumab.
- Other cancer medicines may change treatment risks; combinations require specialist monitoring.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.